ABSTRACT
To determine the prevalence of vaccine-associated paralytic poliomyelitis (VAPP) in immunodeficient infants, we reviewed all documented cases caused by immunodeficiency-associated vaccine-derived polioviruses in Iran from 1995 through 2008. Changing to an inactivated polio vaccine vaccination schedule and introduction of screening of neonates for immunodeficiencies could reduce the risk for VAPP infection.
Subject(s)
Immunologic Deficiency Syndromes/complications , Poliomyelitis/etiology , Poliovirus Vaccine, Oral/adverse effects , Child, Preschool , Female , Humans , Infant , Iran , Male , Time FactorsABSTRACT
Type 3 immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) were isolated from a 15-month-old Iranian boy with acute flaccid paralysis (AFP) who was subsequently diagnosed with X-linked agammaglobulinemia (XLA). VP1 nucleotide sequences of the two isolates differed from Sabin 3 by 2.0% and 2.1% and from each other by 0.6%. Although the key determinant of attenuation and temperature sensitivity in the 5'-untranslated region (U(472)-->C) had reverted, a second capsid-region determinant (VP3:Phe(091)) was unchanged, but a presumptive suppressor (VP1:Ala(054)-->Val) was found. The isolates were Sabin 3/Sabin 1 recombinants, sharing a single recombination breakpoint in the 2C region. Although the two isolates were antigenically distinct from Sabin 3, only one amino acid replacement was found in the neutralizing antigenic sites (VP3:Ser(059)-->Asn in site 3). The patient was placed on intravenous immunoglobulin (IVIG) therapy within 9 days of onset of AFP, and iVDPV excretion ceased thereafter, but the patient remained severely paralyzed until his death approximately 11 months after paralysis. No secondary AFP cases were found, and none of the seven tested contacts of the patient were found to be infected with poliovirus.
Subject(s)
Agammaglobulinemia/complications , Genetic Diseases, X-Linked/complications , Poliomyelitis/complications , Poliomyelitis/virology , Poliovirus Vaccine, Oral/adverse effects , Poliovirus/isolation & purification , Capsid Proteins/genetics , Cell Line, Tumor , Humans , Immunoglobulins/therapeutic use , Immunologic Factors/therapeutic use , Infant , Iran , Male , Molecular Sequence Data , Poliomyelitis/drug therapy , Poliomyelitis/prevention & control , Poliovirus/classification , Poliovirus/geneticsABSTRACT
Vaccine-associated paralytic poliomyelitis (VAPP) is a rare complication of oral polio vaccine. We describe a fatal case of VAPP in an 8-month-old boy with Major Histocompatibility Class II deficiency. The isolated poliovirus was a Sabin type 2-type 1 recombinant that showed 1.4% VP1 divergence from Sabin type 2.